Related Experiment Videos
Hypertriglyceridemia and pancreatitis associated with estramustine phosphate.
1Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, U.S.A.
American Journal of Clinical Oncology
|August 2, 2002
Summary
Estramustine phosphate, used for prostate cancer, may cause severe hypertriglyceridemia and pancreatitis in some patients. This rare complication highlights the need for monitoring triglyceride levels during treatment.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Estramustine phosphate is an antineoplastic agent with known estrogenic side effects.
- Hypertriglyceridemia is not a commonly recognized complication of estramustine phosphate therapy.
Observation:
- A case study of a 59-year-old man with hormone-refractory prostate cancer treated with estramustine phosphate, docetaxel, and carboplatin.
- The patient developed severe hypertriglyceridemia (12,210 mg/dl) and pancreatitis after three cycles of treatment.
Findings:
- Estramustine phosphate was identified as a potential cause of severe hypertriglyceridemia and pancreatitis.
- Discontinuation of estramustine phosphate led to the resolution of hypertriglyceridemia and pancreatitis.
Implications:
- This case suggests estramustine phosphate can induce hypertriglyceridemia in susceptible individuals.
- Clinicians should consider monitoring triglyceride levels in patients receiving estramustine phosphate, especially those with risk factors.